# PeptideScanner evidence objects: Apraglutide

Every published version of the records placed with Apraglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/apraglutide.json. Selected public evidence only; not medical advice.

- Objects: 8
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct04627025-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT04627025

> PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04627025-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-11-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04627025-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04627025-apraglutide-v1
- Content SHA-256: `d9e0b47103cd2b27c2991fbbf0cc2c671d97698ab302c7f66d11732ca204bda5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04627025 ([`ctg-observation-nct04627025-2024-11-27-33862c3edfc1`](#source-ctg-observation-nct04627025-2024-11-27-33862c3edfc1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04627025-2024-11-27-33862c3edfc1`](#source-ctg-observation-nct04627025-2024-11-27-33862c3edfc1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04627025-2024-11-27-33862c3edfc1`](#source-ctg-observation-nct04627025-2024-11-27-33862c3edfc1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04627025-2024-11-27-33862c3edfc1`](#source-ctg-observation-nct04627025-2024-11-27-33862c3edfc1))

### Sources

<a id="source-ctg-observation-nct04627025-2024-11-27-33862c3edfc1"></a>
- **ClinicalTrials.gov record NCT04627025 · retained source version 2024-11-27:33862c3edfc1d142d183d19484af2a0576a306288f110a84f44d6dec45422596** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04627025) (`ctg-observation-nct04627025-2024-11-27-33862c3edfc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04627025." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04627025-apraglutide-v1 SHA-256: d9e0b47103cd2b27c2991fbbf0cc2c671d97698ab302c7f66d11732ca204bda5.

---

<a id="clinicaltrials-gov-nct04699032-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT04699032

> PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04699032-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04699032-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04699032-apraglutide-v1
- Content SHA-256: `b7bfbf5c4c34c23b1d2c30fa739289d6ea779653bd48b7c3650ecdfd5dae7d5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04699032 ([`ctg-observation-nct04699032-2024-10-26-630253818817`](#source-ctg-observation-nct04699032-2024-10-26-630253818817))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04699032-2024-10-26-630253818817`](#source-ctg-observation-nct04699032-2024-10-26-630253818817))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04699032-2024-10-26-630253818817`](#source-ctg-observation-nct04699032-2024-10-26-630253818817))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04699032-2024-10-26-630253818817`](#source-ctg-observation-nct04699032-2024-10-26-630253818817))

### Sources

<a id="source-ctg-observation-nct04699032-2024-10-26-630253818817"></a>
- **ClinicalTrials.gov record NCT04699032 · retained source version 2024-10-26:6302538188175ec900236f873275253b70f3e00a3e5139b54c94fed7f630ed5d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04699032) (`ctg-observation-nct04699032-2024-10-26-630253818817`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04699032." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04699032-apraglutide-v1 SHA-256: b7bfbf5c4c34c23b1d2c30fa739289d6ea779653bd48b7c3650ecdfd5dae7d5c.

---

<a id="clinicaltrials-gov-nct04964986-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT04964986

> PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct04964986-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04964986-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04964986-apraglutide-v1
- Content SHA-256: `1e91566139cc15e7934a797086b73a3d3101f147a066c4c764c0f40ffe2b462c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04964986 ([`ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9`](#source-ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9`](#source-ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9`](#source-ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9`](#source-ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9))

### Sources

<a id="source-ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9"></a>
- **ClinicalTrials.gov record NCT04964986 · retained source version 2025-06-18:0f19bafdb5c9e2355f6aa64060d01b77ba5a45f44584e890f7f3f8e932df50c5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04964986) (`ctg-observation-nct04964986-2025-06-18-0f19bafdb5c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04964986." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct04964986-apraglutide-v1 SHA-256: 1e91566139cc15e7934a797086b73a3d3101f147a066c4c764c0f40ffe2b462c.

---

<a id="clinicaltrials-gov-nct05018286-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT05018286

> PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05018286-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05018286-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05018286-apraglutide-v1
- Content SHA-256: `ee5898a99f69d68a92188cd3829479e782590d3fb8a5e47faaaf4173a2c345dc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05018286 ([`ctg-observation-nct05018286-2025-07-02-f176ac852b48`](#source-ctg-observation-nct05018286-2025-07-02-f176ac852b48))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05018286-2025-07-02-f176ac852b48`](#source-ctg-observation-nct05018286-2025-07-02-f176ac852b48))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05018286-2025-07-02-f176ac852b48`](#source-ctg-observation-nct05018286-2025-07-02-f176ac852b48))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05018286-2025-07-02-f176ac852b48`](#source-ctg-observation-nct05018286-2025-07-02-f176ac852b48))

### Sources

<a id="source-ctg-observation-nct05018286-2025-07-02-f176ac852b48"></a>
- **ClinicalTrials.gov record NCT05018286 · retained source version 2025-07-02:f176ac852b4898df9697babe58bebd3233457b165dcc9034e8a6cd5b55388c8c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05018286) (`ctg-observation-nct05018286-2025-07-02-f176ac852b48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05018286." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05018286-apraglutide-v1 SHA-256: ee5898a99f69d68a92188cd3829479e782590d3fb8a5e47faaaf4173a2c345dc.

---

<a id="clinicaltrials-gov-nct05706623-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT05706623

> PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05706623-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05706623-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05706623-apraglutide-v1
- Content SHA-256: `621aea9070d8e91cc9609a9aa4977fe88ef8c40783e2e4853bdf14864a294ce9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05706623 ([`ctg-observation-nct05706623-2025-07-10-de7774cd90ae`](#source-ctg-observation-nct05706623-2025-07-10-de7774cd90ae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05706623-2025-07-10-de7774cd90ae`](#source-ctg-observation-nct05706623-2025-07-10-de7774cd90ae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05706623-2025-07-10-de7774cd90ae`](#source-ctg-observation-nct05706623-2025-07-10-de7774cd90ae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05706623-2025-07-10-de7774cd90ae`](#source-ctg-observation-nct05706623-2025-07-10-de7774cd90ae))

### Sources

<a id="source-ctg-observation-nct05706623-2025-07-10-de7774cd90ae"></a>
- **ClinicalTrials.gov record NCT05706623 · retained source version 2025-07-10:de7774cd90aed967f50268c2a2a452a1356e47651dd9c7cb5d2e40ae875b2c15** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05706623) (`ctg-observation-nct05706623-2025-07-10-de7774cd90ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05706623." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05706623-apraglutide-v1 SHA-256: 621aea9070d8e91cc9609a9aa4977fe88ef8c40783e2e4853bdf14864a294ce9.

---

<a id="clinicaltrials-gov-nct05995704-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT05995704

> PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct05995704-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05995704-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05995704-apraglutide-v1
- Content SHA-256: `4837b3c597a7457be0ad12c2eeeae3972b46d63d8e175a6bad276d256ec30995`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05995704 ([`ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9`](#source-ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9`](#source-ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9`](#source-ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9`](#source-ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9))

### Sources

<a id="source-ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9"></a>
- **ClinicalTrials.gov record NCT05995704 · retained source version 2024-10-24:e60a3e5bc0b9d57b7161bd3896366456523c48b9c5e0fe222774340bfcf9eb4b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05995704) (`ctg-observation-nct05995704-2024-10-24-e60a3e5bc0b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05995704." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct05995704-apraglutide-v1 SHA-256: 4837b3c597a7457be0ad12c2eeeae3972b46d63d8e175a6bad276d256ec30995.

---

<a id="clinicaltrials-gov-nct06002555-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT06002555

> PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct06002555-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06002555-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct06002555-apraglutide-v1
- Content SHA-256: `033788de0f8990f4d322ca3cee48eda5062a255ecfee7b6fb78bdb9889fefdd5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06002555 ([`ctg-observation-nct06002555-2024-10-26-9f56c914ab5f`](#source-ctg-observation-nct06002555-2024-10-26-9f56c914ab5f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct06002555-2024-10-26-9f56c914ab5f`](#source-ctg-observation-nct06002555-2024-10-26-9f56c914ab5f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct06002555-2024-10-26-9f56c914ab5f`](#source-ctg-observation-nct06002555-2024-10-26-9f56c914ab5f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06002555-2024-10-26-9f56c914ab5f`](#source-ctg-observation-nct06002555-2024-10-26-9f56c914ab5f))

### Sources

<a id="source-ctg-observation-nct06002555-2024-10-26-9f56c914ab5f"></a>
- **ClinicalTrials.gov record NCT06002555 · retained source version 2024-10-26:9f56c914ab5fa3140a55576759f3bb1da291468f4fc2ed7d23fe0e3b86a09936** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06002555) (`ctg-observation-nct06002555-2024-10-26-9f56c914ab5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06002555." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct06002555-apraglutide-v1 SHA-256: 033788de0f8990f4d322ca3cee48eda5062a255ecfee7b6fb78bdb9889fefdd5.

---

<a id="clinicaltrials-gov-nct07742735-apraglutide-v1"></a>

## ClinicalTrials.gov record NCT07742735

> PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide.

- Evidence object: `story:clinicaltrials-gov-nct07742735-apraglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07742735-apraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct07742735-apraglutide-v1
- Content SHA-256: `918ec1fdfa7f1bfe9d1feb99dc2c98387c39e42d5bd2b150414b601862a81fe5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07742735 ([`ctg-observation-nct07742735-2026-08-04-4023f7314739`](#source-ctg-observation-nct07742735-2026-08-04-4023f7314739))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct07742735-2026-08-04-4023f7314739`](#source-ctg-observation-nct07742735-2026-08-04-4023f7314739))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide. ([`ctg-observation-nct07742735-2026-08-04-4023f7314739`](#source-ctg-observation-nct07742735-2026-08-04-4023f7314739))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07742735-2026-08-04-4023f7314739`](#source-ctg-observation-nct07742735-2026-08-04-4023f7314739))

### Sources

<a id="source-ctg-observation-nct07742735-2026-08-04-4023f7314739"></a>
- **ClinicalTrials.gov record NCT07742735 · retained source version 2026-08-04:4023f7314739caea80157c1523434645be32b32a965d3d0f20c7c1b5dcdb3218** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07742735) (`ctg-observation-nct07742735-2026-08-04-4023f7314739`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07742735." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/apraglutide.json#clinicaltrials-gov-nct07742735-apraglutide-v1 SHA-256: 918ec1fdfa7f1bfe9d1feb99dc2c98387c39e42d5bd2b150414b601862a81fe5.

